25th September 2024，UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with moderate to severe plaque psoriasis treated with bimekizumab, an IL-17A and IL-17F inhibitor. These post-hoc analyses include maintenance of response through four years in bimekizumab patients who achieved near-complete or complete skin clearance after one year, and the clinical response up to four years in patients switching to bimekizumab following an inadequate response to either adalimumab, ustekinumab, or secukinumab. These data are presented at the 33rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands, 25–28 September 2024. In addition, the design and rationale behind the exploratory, multicentre, open-label Phase 3b bimekizumab study, BE UNIQUE, that is exploring the fast onset, high level and durability of clinical and molecular responses in patients with psoriatic disease are also shared.
“Given the chronic nature of psoriasis, it is critically important to evaluate long-term response of treatments. Achieving completely clear skin is a key goal for people living with moderate to severe plaque psoriasis and results presented at EADV 2024 showed that over 7 out of 10 patients who achieved complete skin clearance after one year, maintained this response at four years,” said Professor Richard Warren, Northern Care Alliance NHS Foundation Trust and The University of Manchester, United Kingdom.
“The four-year data presented at EADV 2024 demonstrate maintenance of complete skin clearance for patients continuing treatment with bimekizumab,” said Fiona du Monceau, Executive Vice President, Head of Patient Evidence, UCB. “We are also proud to share the design of BE UNIQUE, a Phase 3b study investigating whether the durability of clinical response with bimekizumab is associated with molecular and cellular changes in skin, blood and joints of patients with psoriatic disease.”
Click here to learn more about our IL-17 catalog！
